Cap polyposis is a rare disorder with characteristic endoscopic and histological features; its etiology is still unknown, and no specific treatment has been established. We report a case of cap polyposis that improved remarkably after infliximab infusion and had no recurrence for 3 years. (Gut and Liver 2009;3: 325-328)
INTRODUCTION
Cap polyposis is a rare but distinct disorder with characteristic endoscopic and histological features. 1, 2 It is characterized by multiple distinctive erythematous, inflammatory colonic polyps located from the rectum to the distal colon. And the polyps are covered with fibrinopurulent mucus which appears like a 'cap.' The common symptoms are mucous and bloody diarrhea with abdominal pain and tenesmus. The etiology of this disease is still unknown, and no specific treatment has been established. There have been a few reports about the cases of cap polyposis responsive to infliximab. 3 Herein we report a cap polyposis that was remarkably improved after a single infliximab infusion and had no recurrence for 3 years.
CASE REPORT
A 58-year-old woman was admitted to our hospital because of mucous bloody stools, frequent defecation and tenesmus for 2 weeks. One month ago, the patient had been managed in other hospital with 2nd generation cephalosporin antibiotics because of community acquired pneumonia. On physical examination, abdomen was soft and there was no tenderness or palpable mass. Hemoglobin was 14.5 g/dL, white blood cell count was 6,380/mm 3 , platelet count was 319,000/mm 3 and data of C-reactive protein or erythrocyte sedimentation rate were not increased. Stool occult blood test was positive, but, Clostridium difficile antigen assay of stool was negative.
Colonoscopy showed about 20 reddish sessile polyps covered with white purulent exudates, and scattered hyperemia on rectum and sigmoid colon. The polyps were located on apices of mucosal fold (Fig. 1) . The histological finding of sessile polyp indicated chronic and acute inflammations with acute cryptitis. We first diagnosed pseudomembranous colitis based on patient's history of antibiotics administration and colonoscopic finding. However, there was no clinical symptom improvement after oral administration of 250 mg metronidazol qid for 3 weeks.
The colonoscopic finding for follow up showed no improvement, and additional biopsy was performed. Histological finding showed that the polyps were consisted of elongated, tortuous, and hyperplastic crypts that attenuated toward the surface (Fig. 2) . Heavy infiltration of inflammatory cells, ulcerated mucosal surface and fibrinopurulent exudates are characteristic of the so-called "cap polyp." On the basis of these characteristic colonoscopic and histologic findings, therefore, the patient was diagnosed with cap polyposis.
We considered conservative management and bowel ha- bitual correction to avoid straining at defecation. After 12 months of these managements, there was no improvement of clinical symptom and colonoscopic finding. Then, we considered surgical management or infliximab infusion. Therefore, we first administered 5 mg/kg dose of infliximab. At 7th days, following the infliximab infusion, clinical improvement occurred. After 4 weeks of infliximab infusion, colonoscopy revealed that the multiple sessile polyps decreased in size and numbers (Fig. 3) , and no side effect of infliximab was observed. Therefore, we decided to follow up the patient with no additional administration of infliximab. For 3 years, the patient experienced no clinical symptom recurrence, and the last colonoscopy revealed almost complete mucosal recovery except for tiny scant scars (Fig. 4) .
DISCUSSION
Common clinical manifestation of cap polyposis is mucous bloody diarrhea lasting for weeks to months, and women are mostly afflicted. Tenesmus, rectal bleeding, abdominal pain, constipation, weight loss, and hypoproteinemia have also been reported. 3, 4 Epidemiology and etiology of cap polyposis have not been well known. Several case reports have suggested a few treatment modalities, based on etiological hypothesis; anti-inflammatory agent, antibiotics, immunomodulators, and endoscopic and surgical therapy ( Table 1 ). However optimal treatment has not yet been established. The effectiveness and administration schedule of infliximab for cap polyposis also have not yet been established. One report described complete remission after four infusions of infliximab at 0, 8, 12, and 24 weeks, however another reports showed no benefit after a similar treatment. 3, 9 In our present case, the patient fortunately achieved remarkable clinical, endoscopic and histological responses after single infusion of infliximab. The short term response of our patient was published in Korean. 20 Our present case is the long term follow up result after 3 years. Furthermore, resolution of the disease maintained for 36 months. Consequently, our present case might support the hypothesis that inflammation has some role in the pathogenesis of cap polyposis. 3 Of course, additional studies about cap polyposis treated with infliximab infusion, including its optimal dosage and administration schedule, are needed. Nevertheless we suggest that infliximab might be a good treatment modality for cap polyposis patients who are refractory to conservative management.
